ETRA NASDAQ
Electra Therapeutics Inc.
1W: -3.3%
1M: -24.7%
YTD: -43.2%
$8.52
+0.15 (+1.79%)
Weekly Expected Move ±7.7%
$7
$8
$9
$9
$10
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$40.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$180.7M
52W Range8.26-15.5
Volume176,272
Avg Volume687,628
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOQuehuong Dong
Employees46
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-09-18
Websiteelectra-therapeutics.com
230 E Grand Avenue
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
About Electra Therapeutics Inc.
Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | C-Conversion | 2,002,310 | — | 2026-09-21 |
| ORBIMED ADVISORS LLC | C-Conversion | 1,087,934 | — | 2026-09-21 |
| ORBIMED ADVISORS LLC | C-Conversion | 1,703,314 | — | 2026-09-21 |
| ORBIMED ADVISORS LLC | P-Purchase | 333,333 | $15.00 | 2026-09-21 |
| ORBIMED ADVISORS LLC | C-Conversion | 758,279 | — | 2026-09-21 |